Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Change in Inventory (2018 - 2025)

10x Genomics (TXG) has disclosed Change in Inventory for 8 consecutive years, with -$5.6 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory rose 41.97% to -$5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$28.0 million through Dec 2025, down 385.91% year-over-year, with the annual reading at -$28.0 million for FY2025, 385.91% down from the prior year.
  • Change in Inventory hit -$5.6 million in Q4 2025 for 10x Genomics, up from -$7.3 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $9.9 million in Q1 2024 to a low of -$9.6 million in Q4 2024.
  • Historically, Change in Inventory has averaged $1.3 million across 5 years, with a median of $2.8 million in 2022.
  • Biggest five-year swings in Change in Inventory: crashed 632.08% in 2023 and later skyrocketed 2113.14% in 2024.
  • Year by year, Change in Inventory stood at $8.8 million in 2021, then tumbled by 83.71% to $1.4 million in 2022, then plummeted by 632.08% to -$7.6 million in 2023, then fell by 26.33% to -$9.6 million in 2024, then soared by 41.97% to -$5.6 million in 2025.
  • Business Quant data shows Change in Inventory for TXG at -$5.6 million in Q4 2025, -$7.3 million in Q3 2025, and -$7.0 million in Q2 2025.